VIDEO: Phase 3 bel-sar trial focuses on choroidal melanoma

ByJill Hopkins, MD

ByAnthony DeFino

Fact checked byChristine Klimanskis, ELS

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jill Hopkins, MD, of Aura Biosciences discusses a phase 3 program in ocular oncology.

The trial, which is currently enrolling, will investigate belzupacap sarotalocan (bel-sar) delivered through a suprachoroidal injection and activated with a laser in patients with choroidal melanoma. According to Hopkins, a phase 2 program demonstrated encouraging results in tumor regression and vision preservation.

“This potential for bel-sar to be effective in stopping tumor growth and preserving vision would show a significant paradigm shift for patients who currently have radiotherapy as their only available option,” she said.

Published by:

Sources/Disclosures

Collapse

Source:

Hopkins J. A new potential option for uveal melanoma — The science of bel-sar and phase 3 CoMpass trial. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Disclosures: Hopkins reports being chief medical officer and president of research and development at Aura Biosciences.

Clinical Trials at the Summit meeting

Read more

VIDEO: Phase 3 bel-sar trial focuses on choroidal melanoma

Related Content